Pretransplant cryptococcosis and outcome after liver transplantation

Liver Transplantation

Volumn 16, Issue 4, 2010, Pages 499-502

  Sifri, Costi D ^a   Sun, Hsin Yun ^b,c   Cacciarelli, Thomas V ^b,d   Wispelwey, Brian ^a   Pruett, Timothy L ^a   Singh, Nina ^b,d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; METHYLPREDNISOLONE; VALACICLOVIR; VANCOMYCIN; ANTIFUNGAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANAMNESIS; ARTICLE; BILE LEAKAGE; BRAIN DAMAGE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CRYPTOCOCCOSIS; DRUG DOSE INCREASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG NODULE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; COMPLICATION; FIBROSIS; LIVER FAILURE; MIDDLE AGED; PROCEDURES; TIME; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; FIBROSIS; FLUCONAZOLE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 77950674205     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Singh N, Husain S, De Vera M, Gayowski T, Cacciarelli TV. Cryptococcus neoformans infection in patients with cirrhosis, including liver transplant candidates. Medicine (Baltimore) 2004;83:188-192.
2. Jean SS, Fang CT, Shau WY, Chen YC, Chang SC, Hsueh PR, et al. Cryptococcaemia: clinical features and prognostic factors. QJM 2002;95:511-518.
3. Chuang YM, Ho YC, Chang HT, Yu CJ, Yang PC, Hsueh PR. Disseminated cryptococcosis in HIV-uninfected patients. Eur J Clin Microbiol Infect Dis 2008;27:307-310.
4. Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: current state of the science. Clin Infect Dis 2008;47:1321-1327.
5. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 1999;37:3204-3209.
6. Haugen RK, Baker RD. The pulmonary lesions in cryptococcosis with special reference to subpleural nodules. Am J Clin Pathol 1954;24:1381-1390.
7. Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995;21:1077-1089.
8. Wormley FL Jr, Perfect JR, Steele C, Cox GM. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect Immun 2007;75:1453-1462.
9. Milam JE, Herring-Palmer AC, Pandrangi R, McDonald RA, Huffnagle GB, Toews GB. Modulation of the pulmonary type 2 T-cell response to Cryptococcus neoformans by intratracheal delivery of a tumor necrosis factor alpha-expressing adenoviral vector. Infect Immun 2007;75:4951-4958.
10. Kawakami K, Kohno S, Kadota J, Tohyama M, Teruya K, Kudeken N, et al. T cell-dependent activation of macrophages and enhancement of their phagocytic activity in the lungs of mice inoculated with heat-killed Cryptococcus neoformans: involvement of IFN-gamma and its protective effect against cryptococcal infection. Microbiol Immunol 1995;39:135-143.
11. Flesch IE, Schwamberger G, Kaufmann SH. Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans. J Immunol 1989;142:3219-3224.
12. Muller U, Stenzel W, Kohler G, Werner C, Polte T, Hansen G, et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol 2007;179:5367-5377.
13. Blackstock R, Murphy JW. Role of interleukin-4 in resistance to Cryptococcus neoformans infection. Am J Respir Cell Mol Biol 2004;30:109-117.
14. Decken K, Kohler G, Palmer-Lehmann K, Wunderlin A, Mattner F, Magram J, et al. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun 1998;66:4994-5000.
15. Kawakami K, Hossain Qureshi M, Zhang T, Koguchi Y, Xie Q, Kurimoto M, et al. Interleukin-4 weakens host resistance to pulmonary and disseminated cryptococcal infection caused by combined treatment with interferongamma- inducing cytokines. Cell Immunol 1999;197: 55-61.
16. Atalar K, Afzali B, Lord G, Lombardi G. Relative roles of Th1 and Th17 effector cells in allograft rejection. Curr Opin Organ Transplant 2009;14:23-29.
17. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148:32-46.
18. Strom TB, Roy-Chaudhury P, Manfro R, Zheng XX, Nickerson PW, Wood K, et al. The Th1/Th2 paradigm and the allograft response. Curr Opin Immunol 1996;8:688-693.
19. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009;48:101-107.
20. Kontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F, Gupta KL, et al. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2008;52:735-738.
21. Silveira FP, Husain S, Kwak EJ, Linden PK, Marcos A, Shapiro R, et al. Cryptococcosis in liver and kidney transplant recipients receiving anti-thymocyte globulin or alemtuzumab. Transpl Infect Dis 2007;9:22-27.
22. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006;26:1730-1744.
23. Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation 2002;74:1477-1478.
24. Sadaba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc 2004;36:3226-3228.
25. Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, et al. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother 2008;42:1711-1716.
26. Iitaka K, McEnery PT, West CD. Successful renal transplantation after generalized cryptococcosis. J Pediatr 1978;92:422-423.
27. Mills SA, Seigler HF, Wolfe WG. The incidence and management of pulmonary mycosis in renal allograft patients. Ann Surg 1975;182:617-626.
28. Swenson RS, Kountz SL, Blank N, Merigan TC. Successful renal allograft in a patient with pulmonary cryptococcus. Arch Intern Med 1969;124:502-506.
29. Concejero A, Chen CL, Lu HI, Eng HL, Liu JW, Yang CH, et al. Granulomatous infections in living donor liver transplant candidates. Paper presented at: 15th Annual International Congress of the International Liver Transplantation Society; July 8-11, 2009; New York, NY. Abstract P-497.
30. Rubin RH, Young LS. Clinical Approach to Infection in the Compromised Host. New York, NY: Kluwer Academic/Plenum; 2002:215-248.
31. Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, et al. Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007;195:756-764.